Reply to thread

Message: <blockquote data-quote="Hyaenidae" data-source="post: 30872963" data-attributes="member: 530392">Key challenge:SNRIs (e.g., venlafaxine, duloxetine, desvenlafaxine, milnacipran, levomilnacipran) increase synaptic norepinephrine and can raise circulating catecholamines and metanephrines, the very analytes used to screen for pheochromocytoma. This produces frequent false-positive biochemical tests. The goal is to obtain at least one reliable set of results uncontaminated by the drug.<hr /> <ol> <li data-xf-list-type="ol">Temporarily withdraw or switch the SNRI</li> </ol><hr />• If the psychiatric risk is low to moderate, taper off the SNRI for ≥2 weeks (≈5 half-lives) before drawing blood or collecting 24-h urine.– Venlafaxine & desvenlafaxine: 5–7 days minimum; 14 days preferred.– Duloxetine: 7–10 days minimum; 14 days preferred.• Manage withdrawal with a short taper (reduce dose every 2–3 days) and start an SSRI (sertraline, escitalopram, fluoxetine) or buspirone if an antidepressant is still needed; these do not interfere with catecholamine testing.• If stopping the SNRI is unsafe (high suicide risk, refractory depression):- Obtain psychiatric clearance for a closely supervised taper that lasts as short as clinically feasible, or- Proceed to alternate biochemical or functional tests (see below).<hr /> <ol> <li data-xf-list-type="ol">Choose the least drug-sensitive biochemical test</li> </ol><hr />• First-line after drug washout: Plasma free metanephrines measured after the patient rests supine for 20–30 min in a quiet room. (Superior sensitivity; modest increase from SNRIs resolves after washout.)• If the SNRI cannot be stopped:– 24-h urinary fractionated metanephrines tend to be less affected than plasma catecholamines but still show some false positives.– Chromogranin A is unaffected by SNRIs but has lower specificity; use only as adjunct.– Urinary 3-methoxytyramine (3-MT) is not influenced by SNRIs and can help rule out head-and-neck paragangliomas, although data are limited.<hr /> <ol> <li data-xf-list-type="ol">Consider a functional suppression test (second line)</li> </ol><hr />• Clonidine suppression test (for borderline‐elevated plasma catecholamines):– Give oral clonidine 0.3 mg after baseline catecholamine draw.– Measure plasma catecholamines again at 3 h.– In true pheochromocytoma, norepinephrine stays elevated; in drug-induced elevation it suppresses by ≥40 % or to <500 pg/mL.– Ensure normal blood pressure and cardiac status before using clonidine.<hr /> <ol> <li data-xf-list-type="ol">Imaging only after unambiguous biochemical confirmation</li> </ol><hr />• CT/MRI adrenal or extra-adrenal, and ¹²³I-MIBG or ⁶⁸Ga-DOTATATE PET, should be performed only when biochemical evidence persists after drug washout or alternate testing confirms excess catecholamine production.<hr /> <ol> <li data-xf-list-type="ol">Practical workflow summary</li> </ol><hr /><ol> <li data-xf-list-type="ol">Psychiatric review → plan SNRI taper (aim ≥2 weeks off). </li> <li data-xf-list-type="ol">During washout: monitor for discontinuation syndrome; cover with SSRI if needed. </li> <li data-xf-list-type="ol">After washout: draw plasma free metanephrines with proper supine rest. </li> <li data-xf-list-type="ol">If still positive or SNRI cannot be stopped: • Repeat test with urinary metanephrines ± 3-MT • Add clonidine suppression test. </li> <li data-xf-list-type="ol">Proceed to imaging only if biochemical tests remain positive. </li> </ol><hr />Take-home point:Because SNRIs reliably elevate catecholamine measurements, the simplest and most reliable way to rule out pheochromocytoma is to stop the SNRI long enough for it to clear, then repeat high-sensitivity plasma free metanephrines under standardized conditions. When withdrawal is impossible, combine the least drug-sensitive analytes with a functional suppression test to reach a confident conclusion.</blockquote>

Verification: Hathara warak wissa keeyada? (Hathara wadi karanna 20)

Top Bottom